These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

106 related articles for article (PubMed ID: 2491287)

  • 61. Corynebacterium parvum treatment of P388 tumor-bearing mice. I. Lysosomal enzyme levels in adherent peritoneal cells and peritoneal lavage fluid.
    Astry CL; Loose LD; Megirian R
    J Immunopharmacol; 1981; 3(1):29-47. PubMed ID: 7252179
    [TBL] [Abstract][Full Text] [Related]  

  • 62. Corynebacterium parvum treatment of P388 tumor-bearing mice. II. Lysosomal enzyme levels associated with P388 tumor cells.
    Astry CL; Loose LD; Megirian R
    J Immunopharmacol; 1981; 3(1):49-66. PubMed ID: 7252180
    [TBL] [Abstract][Full Text] [Related]  

  • 63. Trapping and killing of Candida albicans by Corynebacterium parvum-activated livers.
    Sawyer RT; Moon RJ; Beneke ES
    Infect Immun; 1981 May; 32(2):945-50. PubMed ID: 7019084
    [TBL] [Abstract][Full Text] [Related]  

  • 64. Effect of oral administration of a variety of bacteria on depressed macrophage functions in tumour-bearing rats.
    Iannello D; Bonina L; Delfino D; Berlinghieri MC; Gismondo MR; Mastroeni P
    Ann Immunol (Paris); 1984; 135C(3):345-52. PubMed ID: 6433774
    [TBL] [Abstract][Full Text] [Related]  

  • 65. A comparison of pyrogenicity and related properties seen in a suspension of Corynebacterium parvum and a gramnegative organism.
    Lucken RN; Adlam C; Knight PA
    Dev Biol Stand; 1977; 34():135-41. PubMed ID: 320069
    [TBL] [Abstract][Full Text] [Related]  

  • 66. The restoration of impaired macrophage functions using as immunomodulator the Corynebacterium granulosum-derived P40 fraction.
    Mastroeni P; Bizzini B; Bonina L; Iannello D; Merendino RA; Delfino D; Berlinghieri MC; Leonardi MS; Arena A; Liberto MC
    Immunopharmacology; 1985 Aug; 10(1):27-34. PubMed ID: 2997082
    [TBL] [Abstract][Full Text] [Related]  

  • 67. Tumor-dependent resistance of rat peritoneal macrophages to herpes simplex virus.
    Bonina L; Iannello D; Merendino R; Arena A; Mastroeni P
    Infect Immun; 1983 Feb; 39(2):575-9. PubMed ID: 6299945
    [TBL] [Abstract][Full Text] [Related]  

  • 68. Role of mononuclear phagocytes in decreased hepatic drug metabolism following administration of Corynebacterium parvum.
    Soyka LF; Stephens CC; MacPherson BR; Foster RS
    Int J Immunopharmacol; 1979; 1(2):101-12. PubMed ID: 551956
    [No Abstract]   [Full Text] [Related]  

  • 69. Enhanced thermal response of a rat sarcoma by Corynebacterium parvum.
    Shah SA
    Cancer Lett; 1985 Mar; 26(2):235-40. PubMed ID: 3978610
    [TBL] [Abstract][Full Text] [Related]  

  • 70. Enhanced chemiluminescence production by purified macrophage monolayers from C. parvum-treated mice.
    Bryant SM; Hill HR
    Immunopharmacology; 1981 Feb; 3(1):19-29. PubMed ID: 6262276
    [TBL] [Abstract][Full Text] [Related]  

  • 71. Effect of Corynebacterium parvum, methanol-extraction residue of BCG, and levamisole on macrophage random migration, chemotaxis, and pinocytosis.
    Sher NA; Poplack DG; Blaese RM; Brown TM; Chaparas SD
    J Natl Cancer Inst; 1977 Jun; 58(6):1753-7. PubMed ID: 864753
    [TBL] [Abstract][Full Text] [Related]  

  • 72. Effect of oral administration of different combinations of killed bacteria on some depressed macrophage functions in tumor-bearing rats.
    Iannello D; Bonina L; Delfino D; Berlinghieri MC; Mastroeni P
    Immunopharmacology; 1985 Jun; 9(3):181-7. PubMed ID: 3894286
    [TBL] [Abstract][Full Text] [Related]  

  • 73. The effect of treatment with Corynebacterium parvum on the development and growth of experimental hematogenic metastases of schwannoma in the rat.
    Bash JA; Mandybur TI; Ritschel WA
    Acta Neuropathol; 1985; 68(1):22-6. PubMed ID: 3876679
    [TBL] [Abstract][Full Text] [Related]  

  • 74. Hypercoagulability after immunotherapy with Corynebacterium parvum in man.
    Harenberg J; Baumgärtner A; Fritze D; Zimmermann R
    Blut; 1982 Apr; 44(4):241-7. PubMed ID: 7082858
    [TBL] [Abstract][Full Text] [Related]  

  • 75. Coagulation and fibrinolysis during the infusion of Corynebacterium parvum in man.
    Cederholm-Williams SA; King A; Allington MJ; Gill PG; Sharp AA; Britton BJ
    Br J Cancer; 1978 Jun; 37(6):1074-7. PubMed ID: 678428
    [No Abstract]   [Full Text] [Related]  

  • 76. Investigation of the component of Propionibacterium acnes (Corynebacterium parvum) responsible for macrophage activation.
    Buck GE; Kelly MT
    Infect Immun; 1980 Feb; 27(2):620-7. PubMed ID: 7380542
    [TBL] [Abstract][Full Text] [Related]  

  • 77. Prolonged fever after pleural instillation of Corynebacterium parvum (Coparvax).
    Laroche CM; Britton M
    Thorax; 1987 Oct; 42(10):823-4. PubMed ID: 3424259
    [No Abstract]   [Full Text] [Related]  

  • 78. Optimal conditions for antitumor activity of C. parvum against the ascites form of sarcoma 180.
    Megirian R; Astry CL; Spoor RP; Loose LD
    J Immunopharmacol; 1980; 2(1):99-112. PubMed ID: 7452006
    [TBL] [Abstract][Full Text] [Related]  

  • 79. Effect of Corynebacterium parvum on peripheral blood platelets.
    Jones PD; Sadler TE; Castro JE
    Br J Cancer; 1977 Dec; 36(6):777-82. PubMed ID: 597475
    [TBL] [Abstract][Full Text] [Related]  

  • 80. Corynebacterium parvum and metastatic breast cancer.
    Haskell CM; Sarna GP; Liu PY
    Br J Cancer; 1982 May; 45(5):794-5. PubMed ID: 7044404
    [No Abstract]   [Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 6.